Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Curie-Cancer and DNA Therapeutics Partner in the Fight Against Cancers

Published: Thursday, March 06, 2014
Last Updated: Wednesday, March 05, 2014
Bookmark and Share
Their clinical and translational research program has developed Dbait molecules now in Phase I clinical trial in patients with advanced melanoma.

Curie-Cancer and DNA Therapeutics are renewing their partnership.

The ongoing collaboration will aim to provide a new class of therapeutic cancer products to patients, including those who are resistant to conventional therapies.

Initial clinical results are encouraging
The first molecule based on Dbait technology, DT01, is currently being assessed in combination with radiation therapy, in a Phase I clinical trial for approximately 20 patients with cutaneous metastatic chemotherapy-resistant melanoma.

DT01 is the result of the partnership between Curie-Cancer and DNA Therapeutics. Dr. Christophe Le Tourneau, head of early-phase clinical trials at the Institut Curie and principal investigator for this trial, has already treated the first patients with this unique class of drugs.

Initial results indicate that:
• Cancers that are resistant to conventional therapies, including advanced-stage melanoma, can be treated with Dbait technology
• DT01 is effective and very well-tolerated in combination with radiation therapy
• DT01 has a high potential for development, pending validation by other early-phase clinical trials, particularly in combination with chemotherapy for advanced-stage cancer

The full results from Phase I are expected within the next year.

Dbait, a new class of cancer drugs
Cancer cells can easily repair damage incurred in their DNA from conventional therapies such as chemotherapy and radiation therapy. A proposal has been made to limit this ability to repair by inhibiting an enzyme involved in the process.

“There are multiple DNA repair pathways but there is no single enzyme that is common to all repair pathways,” says Marie Dutreix, CNRS research director at the Institut Curie. “In addition to being effective, the therapeutic approach should also be non-toxic to healthy cells. With Dbait we have a very unique approach.”

“Instead of targeting a specific enzyme of a repair pathway, Dbait works upstream of all repair pathways with regards to detecting damage caused by radiation therapy and/or chemotherapy. By disrupting the localization of the site of this damage, Dbait prevents any repair and kills cancer cells when they divide. What’s noteworthy is that the specific characteristics of cancer cells make them more vulnerable to the effects of Dbait than healthy cells, ensuring that the latter do not die,” says Marie Dutreix.

Curie-Cancer alongside DNA Therapeutics throughout the entire research process
To support this highly promising clinical research program, DNA Therapeutics and Curie-Cancer will focus their work on five key areas:

• Further understanding of the Dbait mechanisms of action, to better explain the lack of toxicity of these inhibitors on normal tissue
• Characterize the most responsive tumors as well as the most efficacious combinations with standard therapies to prepare for future clinical trials
• Identify potential resistance mechanisms to Dbait
• Identify predictive biomarkers for responding to Dbait
• Develop second-generation Dbait molecules with improved pharmacokinetic properties

“We find all the expertise and support that we need from Curie-Cancer,” says Prof. Jian-Sheng Sun, CEO and founder of DNA Therapeutics. “The reputation of the Institut Curie, in terms of the quality of its fundamental and clinical research, speaks for itself. However, the continued support, even during difficult times, from Curie-Cancer and its ability to apply complementary expertise throughout the development process of a drug have definitely contributed the most to our success. While we are in the clinical assessment stage, Curie-Cancer is ready to launch, in partnership with Marie Dutreix and ourselves, a translational research program to support our efforts. The results of this program will be crucial in shortening time-to-market of our product in the best possible conditions.”

“The Institut Curie is pleased with this long-term partnership, which started at the fundamental research stage and continues today to the clinical research stage. Seeing a drug developed in our laboratory then become available to our patients is immensely rewarding. We look forward to the results of the current assessments and hope that this new class of drug can soon be offered to more patients,” says Damien Salauze, director of Curie-Cancer. “Supporting a French SME in its development and seeing these efforts rewarded are another source of satisfaction. This is another example of the values enshrined in the Institut Carnot label we received from the French government in 2011 for our commitment to providing practical solutions for our industry partners and ultimately, for patients."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Curie-Cancer and Servier Continue a Renewed Partnership in Cancer Research
Their joint aim is to identify new therapeutic targets in ‘triple negative’ breast cancers.
Wednesday, January 29, 2014
Curie-Cancer and Sanofi Cooperate in Research on Ovarian Cancer
Preclinical program of translational research tasked with identifying new target proteins.
Wednesday, June 19, 2013
Curie-Cancer and Biolog-id Sign Partnership Agreement
Within the partnership, Curie-Cancer and Biolog-id will develop a pilot system of RFID tags suitable for use in tracking cancer chemotherapy preparations.
Wednesday, June 05, 2013
Curie-Cancer and Roche Strengthen Partnership
Curie-Cancer and Roche build on four years partnership by increasing translational research programs, speeding up development of new cancer treatments.
Friday, May 17, 2013
Curie-Cancer and Vygon Sign a Partnership Agreement Extension
The Curie-Cancer and Vygon partnership will extend over several years and will achieve the development of catheters and implantable ports with increased resistance to nosocomial infections, for launch on the international market.
Tuesday, April 16, 2013
Curie-Cancer and GenoSplice Technology Sign Bioinformatics Partnership Agreement
The innovative partnership is planned to run for several years to develop unique, high value added genomic approaches.
Wednesday, January 30, 2013
Curie-Cancer Funds its First Selection of Five Late-Stage Projects
Funding of these first five projects enables Institut Curie’s discoveries to progress more rapidly to the industrial stage, making innovation available to patients more quickly.
Friday, December 14, 2012
Scientific News
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Specific Variations in RNA Splicing Linked to Breast Cancer
Researchers have identified cellular changes that may play a role in converting normal breast cells into tumors. Targeting these changes could potentially lead to therapies for some forms of breast cancer.
Gene Expression: A Snapshot of Stem Cell Development
New genes found that regulate development of stem cells.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
Editing Genes to Create HIV Killers
Seattle scientists have managed to genetically transform human cells in the lab from HIV targets to HIV killers, and the technique could have implications for cancer and other diseases.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Milestone Single-Biomolecule Imaging Technique May Advance Drug Design
The first nanometer resolved image of individual tobacco mosaic virions shows the potential of low-energy electron holography for imaging biomolecules at a single particle level; a milestone in structural biology and a potential new tool for drug design.
Opening the Door to Safer, More Precise Cancer Therapies
New method regulates when, and how strongly, cancer-killing therapeutic T cells are activated.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos